Scarica l'app Stockscreener
132.69
0.17%
-0.215
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$132.90
Aprire:
$132.77
Volume 24 ore:
139.92K
Relative Volume:
0.15
Capitalizzazione di mercato:
$13.17B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
44.98
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+7.02%
1M Prestazione:
+0.50%
6M Prestazione:
+16.42%
1 anno Prestazione:
-8.50%
Intervallo 1D:
$132.37
$133.53
Intervallo di 1 settimana:
$124.36
$133.53
Portata 52W:
$84.23
$154.87
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
132.74 | 13.18B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
153.72 | 68.30B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.13 | 47.37B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.74 | 43.29B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.07 | 20.49B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.43 | 14.16B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Order flow analysis tools used on Neurocrine Biosciences Inc.2025 Buyback Activity & Daily Profit Focused Screening - Newser
Ranking Neurocrine Biosciences Inc. among high performing stocks via toolsWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Is Neurocrine Biosciences Inc. stock reversal real or fakeQuarterly Earnings Report & Weekly Market Pulse Updates - Newser
Top chart patterns to watch in Neurocrine Biosciences Inc.Dollar Strength & AI Enhanced Trading Alerts - Newser
What’s the recovery path for long term holders of Neurocrine Biosciences Inc.2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - Newser
Published on: 2025-08-16 23:41:15 - Newser
Understanding Neurocrine Biosciences Inc.’s price movementTrade Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - msn.com
Visual analytics tools that track Neurocrine Biosciences Inc. performancePortfolio Value Summary & Low Risk Entry Point Tips - Newser
Reversal Traders Monitor Neurocrine Biosciences Inc. for EntryJuly 2025 Institutional & Weekly Sector Rotation Insights - metal.it
Trendlines Converge — Decision Point for Neurocrine Biosciences Inc.July 2025 Recap & Stock Market Timing Techniques - beatles.ru
Real time social sentiment graph for Neurocrine Biosciences Inc.2025 Big Picture & Technical Confirmation Alerts - Newser
Earnings visualization tools for Neurocrine Biosciences Inc.2025 Price Targets & Precise Trade Entry Recommendations - Newser
Published on: 2025-08-15 16:55:58 - Newser
PNC Financial Services Group Inc. Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
US Bancorp DE Has $412,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Stronger-Than-Expected Q2 Results Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - MSN
Neurocrine Biosciences Director Gorman Buys, Sells 106,322 Shares on 8/7/2025 - AInvest
Neurological Disorder Drugs Market Set to Witness Significant - openPR.com
Will Neurocrine Biosciences Inc. bounce back from current supportWatchlist Summary for Active Day Traders - Newser
What’s next for Neurocrine Biosciences Inc. stock priceFree Daily Growth Stock Pick Reports - Newser
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewswire Inc.
Neurocrine Biosciences shares rise 3.11% after-hours following Nxera Pharma's obesity pipeline progress. - AInvest
This Neurocrine Biosciences Insider Reduced Their Stake By 28% - 富途牛牛
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Neurocrine Biosciences shares fall 1.10% intraday as Nxera Pharma launches obesity drug pipeline. - AInvest
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Tardive Dyskinesia Drugs Market Exclusive Report with Detailed - openPR.com
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded at Wall Street Zen - Defense World
Guggenheim Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $175.00 - MarketBeat
CRENESSITY's Breakout Launch Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
William Blair Analysts Increase Earnings Estimates for NBIX - Defense World
What drives Neurocrine Biosciences Inc. stock priceUnlock powerful trading alerts for success - Jammu Links News
Is Neurocrine Biosciences Inc. a growth stock or a value stockTremendous wealth creation - Jammu Links News
Neurocrine Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - Jammu Links News
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $144.00 at Royal Bank Of Canada - MarketBeat
How does Neurocrine Biosciences Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
How many analysts rate Neurocrine Biosciences Inc. as a “Buy”Dynamic growth stocks - Jammu Links News
What is the risk reward ratio of investing in Neurocrine Biosciences Inc. stockAchieve consistent profits with expert advice - Jammu Links News
What makes Neurocrine Biosciences Inc. stock price move sharplyStay ahead with daily market updates - Jammu Links News
What is the dividend policy of Neurocrine Biosciences Inc. stockAchieve rapid financial growth with expert picks - Jammu Links News
Contradictions in Focus: Analyzing INGREZZA and Crinecerfont's Market Dynamics and Pricing Strategies - AInvest
How volatile is Neurocrine Biosciences Inc. stock compared to the marketExplosive earnings growth - Jammu Links News
Is Neurocrine Biosciences Inc. stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Neurocrine Biosciences Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
NBIX FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript - Insider Monkey
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
0.97%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):